| Literature DB >> 27188289 |
Neslihan Önenli Mungan1, Dinçer Yıldızdaş2, Deniz Kör2, Özden Özgür Horoz2, Faruk İncecik2, Murat Öktem3, Johannes Sander4.
Abstract
Tyrosinemia type I is an autosomal recessively inherited metabolic disease of tyrosine metabolism due to the deficiency of fumarylacetoacetate hydrolase. Clinical manifestations include hepatic failure, cirrhosis, hepatocellular carcinoma, renal fanconi syndrome, and neurologic crisis. With the introduction of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione treatment the prognosis improved with reduced rate of complications. "Neurologic crisis" of tyrosinemia type I is a rare complication seen after discontinuation of treatment characterized with anorexia, vomiting, and hyponatremia in the initial phase continuing with paresthesia and paralysis of the extremities and the diaphragm. Here, we report a tyrosinemia type I patient who admitted to the hospital with nonspecific symptoms such as vomiting, anorexia, weakness, and restlessness only after one month discontinuation of nitisone and diagnosed as neurological crisis.Entities:
Keywords: Neurologic crisis; Nitisone; Polyneuropathy; Tyrosinemia type I
Mesh:
Substances:
Year: 2016 PMID: 27188289 DOI: 10.1007/s11011-016-9833-y
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.584